Karyopharm Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Karyopharm Therapeutics' es Richard Paulson , nombrado en May 2021, tiene una permanencia de 2.92 años. compensación anual total es $2.63M, compuesta por 28.2% salario y 71.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.26% de las acciones de la empresa, por valor de $319.08K. La antigüedad media del equipo directivo y de la junta directiva es de 2.9 años y 4 años, respectivamente.
Información clave
Richard Paulson
Chief Executive Officer (CEO)
US$2.6m
Compensación total
| Porcentaje del salario del CEO | 28.2% |
| Permanencia del CEO | 2.9yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 2.9yrs |
| Promedio de permanencia en la Junta Directiva | 4yrs |
Actualizaciones recientes de la dirección
Recent updates
Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet
Apr 27
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%
Feb 23Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Feb 05Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified
Apr 17Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 17Karyopharm: Market Is Overlooking Growth
Oct 07Karyopharm Therapeutics Q2 2022 Earnings Preview
Aug 03Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU
Jul 20Karyopharm: Another 2 Year Wait For Data
May 05Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates
Feb 19Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position
Dec 04Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls
Sep 16Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Aug 07Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$740k | -US$143m |
| Sep 30 2023 | n/a | n/a | -US$140m |
| Jun 30 2023 | n/a | n/a | -US$142m |
| Mar 31 2023 | n/a | n/a | -US$158m |
| Dec 31 2022 | US$7m | US$697k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$104m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$8m | US$468k | -US$124m |
| Sep 30 2021 | n/a | n/a | -US$206m |
| Jun 30 2021 | n/a | n/a | -US$208m |
| Mar 31 2021 | n/a | n/a | -US$201m |
| Dec 31 2020 | US$1m | n/a | -US$196m |
Compensación vs. Mercado: La compensación total de Richard($USD2.63M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Richard ha sido consistente con los resultados de la empresa en el último año.
CEO
Richard Paulson (56 yo)
2.9yrs
Permanencia
US$2,626,288
Compensación
Mr. Richard A. Paulson, M.B.A. has been a Director of Karyopharm Therapeutics Inc. since February 26, 2020 and has been its Chief Executive Officer and President since May 3, 2021. Mr. Paulson has been an...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.9yrs | US$2.63m | 0.26% $ 310.0k | |
| Executive VP | 5.2yrs | US$1.14m | 0.069% $ 82.3k | |
| Executive VP & Chief Commercial Officer | 2.3yrs | US$1.19m | 0.061% $ 73.0k | |
| Executive VP & Chief Development Officer | 2.2yrs | US$1.11m | 0.032% $ 37.8k | |
| Executive VP | 2yrs | US$1.23m | 0.025% $ 29.4k | |
| Clinical Consultant | 14.3yrs | US$208.33k | 0% $ 0 | |
| Co-Founder & Chairman of Scientific Advisory Board | 16.3yrs | US$6.04m | 0.73% $ 872.7k | |
| Vice President of Finance | 5.3yrs | sin datos | sin datos | |
| Senior Vice President of Investor Relations | 2.1yrs | sin datos | sin datos | |
| Senior VP | 3.3yrs | US$2.06m | 0.037% $ 44.0k | |
| Chief Compliance Officer | 1.5yrs | sin datos | sin datos | |
| Vice President of Corporate Communications | no data | sin datos | sin datos |
2.9yrs
Permanencia media
50.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KPTI se considera experimentado (2.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.2yrs | US$2.63m | 0.26% $ 310.0k | |
| Clinical Consultant | 13.5yrs | US$208.33k | 0% $ 0 | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | US$6.04m | 0.73% $ 872.7k | |
| Independent Director | 3.4yrs | US$128.33k | 0% $ 0 | |
| Independent Director | 11yrs | US$148.33k | 0% $ 0 | |
| Independent Director | 10.5yrs | US$138.33k | 0.039% $ 46.5k | |
| Lead Independent Director | 11.3yrs | US$173.33k | 0.012% $ 14.0k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.7yrs | US$138.33k | 0% $ 0 | |
| Independent Director | less than a year | US$81.49k | sin datos | |
| Member of Scientific Advisory Board | 3.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 3.9yrs | sin datos | sin datos |
4.0yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de KPTI se considera experimentada (4 años de antigüedad promedio).